Why is the Cochlear share price slipping on Wednesday?

What's going on with Cochlear shares?

| More on:
An older woman tries to listen by cupping her ear.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Cochlear shares dip 1.5% to $203.84 during morning trade
  • The company's shares are trading ex-dividend today
  • Eligible shareholders will receive a dividend payment of $1.45 per share on 17 October

The Cochlear Limited (ASX: COH) share price is heading south on Wednesday morning.

This comes amid the S&P/ASX 200 Index (ASX: XJO) falling wayside today after global markets dipped on the expectation that the United States Federal Reserve will lift interest rates by 75 basis points.

At the time of writing, the hearing solution company's shares are down 1.5% to $203.84.

Why are Cochlear shares falling on Wednesday?

Investors are offloading the Cochlear share price as it trades ex-dividend today.

This means if you purchased the company's shares yesterday or before, you will be eligible for the latest dividend.

However, when a company's shares trade ex-dividend, the share price tends to fall in proportion to the dividend paid out. This can also vary on how the market is tracking for the day, as well as investor sentiment.

For those eligible for Cochlear's final dividend, shareholders will receive a payment of $1.45 per share on 17 October.

The dividend is 40% franked.

Are Cochlear shares a buy now?

Following the company's financial scorecard, a number of brokers weighed in on the Cochlear share price.

As reported by ANZ Share Investing, analysts at Morgan Stanley raised its price target by 4.1% to $202 for Cochlear shares.

In addition, the team at Wilsons raised its target by 4% to $245 apiece. Based on the current share price, this implies an upside of roughly 20%.

On the other hand, Macquarie cut its rating to underperform from neutral and slashed its price target by 1.5% to $194.

This indicates a downside of 5% from where Cochlear shares trade today.

Cochlear share price summary

The Cochlear share price has dropped 13.8% over the past 12 months.

In comparison, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down around14% for the same period.

Based on today's price, Cochlear commands a market capitalisation of roughly $13.61 billion, and has a dividend yield of 1.4%.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

medical doctor performing surgery using surgical instruments
Healthcare Shares

Biotech company implants heart device in world first

This biotech company has implanted a heart device as part of a clinical trial looking to open up new markets.

Read more »

Person pressing the buy button on a smartphone.
Healthcare Shares

Why this buy rated ASX 200 healthcare share is tipped to surge 52%

A leading investment expert forecasts a big rebound for this $8 billion ASX healthcare share.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on big news

This stock is getting a lot of attention from investors on Wednesday. But why?

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

How much further upside is there for Mesoblast shares after soaring 23% in a month?

Could FDA approval send this healthcare stock towards further gains?

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Is this soaring ASX 200 healthcare share just getting started?

If its lead therapy gets US approval, the stock can continue to climb.

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Own CSL shares? Here are the key dates for 2026

It's been a bad year for CSL shares. What's ahead in 2026?

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Healthcare Shares

Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Investors are piling into the ASX 300 healthcare share on Tuesday. Let’s see why.

Read more »